Melanotan I vs Melanotan II: Tanning Efficacy

Introduction

Melanotan I (MT-I, afamelanotide) and Melanotan II (MT-II) are synthetic melanocortin analogs developed to stimulate melanogenesis (tanning) and photoprotection. Both are analogs of alpha-melanocyte-stimulating hormone (α-MSH) but differ significantly in receptor selectivity, potency, pharmacokinetics, and side effect profiles.

Peptide Characteristics

Parameter	Melanotan I	Melanotan II
Amino acid count	13	7
Sequence	Ac-Ser¹-Tyr²-Ser³-Nle⁴-Glu⁵-His⁶-D-Phe⁷-Arg⁸-Trp⁹-Gly¹⁰-Lys¹¹-Pro¹²-Val¹³-NH₂	Ac-Nle⁴-cyclo[Asp⁵-D-Phe⁷-Lys¹⁰]-NH₂
Molecular weight	~1,647 Da	~1,024 Da
Structure	Linear	Cyclic (lactam bridge)
Half-life	~30 minutes	~2–3 hours
Receptor selectivity	High MC1R selectivity	Non-selective MC1R/MC3R/MC4R

Mechanism of Action

Melanogenesis Pathway

Both peptides activate melanocortin-1 receptors (MC1R) on melanocytes, initiating melanin synthesis:

MT-I or MT-II → MC1R → Gαs → ↑cAMP → PKA → CREB → MITF transcription
MITF → Tyrosinase, TRP-1, TRP-2 → Melanin synthesis → Eumelanin (brown/black)

Receptor Selectivity

Melanotan I

High selectivity for MC1R (melanocyte receptor)
Minimal MC3R/MC4R activation at tanning doses
Preferential eumelanin production (brown/black pigment)
Lower risk of off-target effects

Melanotan II

Non-selective melanocortin receptor agonist
Activates MC1R, MC3R, MC4R, and MC5R
Mixed melanin production (eumelanin + some pheomelanin)
MC3R/MC4R activation causes appetite suppression and sexual effects
MC5R activation may contribute to sebaceous gland stimulation

Tanning Efficacy

Onset and Duration

Parameter	Melanotan I	Melanotan II
Time to visible tan	1–2 weeks	3–5 days
Time to peak tan	4–6 weeks	2–3 weeks
Duration after cessation	2–3 months	1–2 months
Tan persistence	Longer	Shorter

Tan Quality

Melanotan I

Produces deep, natural-appearing tan
More uniform pigmentation
Eumelanin-dominant (brown/black)
Better UV protection (SPF ~3 increase)
Tan fades gradually

Melanotan II

Produces rapid, darker initial tan
May appear more “artificial” in tone
Mixed melanin composition
Less consistent UV protection
Tan fades more rapidly

Dose-Response Comparison

Dose Level	Melanotan I	Melanotan II
Low	Mild darkening (2–3 weeks)	Moderate darkening (1 week)
Moderate	Natural tan (4 weeks)	Deep tan (2 weeks)
High	Deep tan (3 weeks)	Very dark tan (1 week) + more side effects

UV Exposure Synergy

Both peptides require UV exposure (sun or artificial) for optimal tanning:

With UV: 50–100% faster tanning, deeper pigment
Without UV: Minimal visible tanning (subclinical melanogenesis)
UV dose reduction: 50–80% less UV needed for equivalent tan
Photoprotection: Both provide modest UV protection through increased melanin

Side Effect Profiles

Melanotan I

Side Effect	Incidence	Severity
Nausea	10–20%	Mild-Moderate
Flushing	15–25%	Mild
Headache	5–10%	Mild
Fatigue	5–10%	Mild
Appetite suppression	10–15%	Mild
Injection site reactions	10–15%	Mild
Sexual arousal/libido changes	Rare at tanning doses	—

Melanotan II

Side Effect	Incidence	Severity
Nausea	30–50%	Moderate-Severe
Flushing	40–60%	Moderate
Headache	20–30%	Moderate
Appetite suppression	30–40%	Moderate
Spontaneous erections (males)	20–40%	Significant
libido increase (both sexes)	20–30%	Moderate
Blood pressure changes	10–20%	Mild-Moderate
Darkening of moles	Variable	Monitor
Injection site reactions	20–30%	Moderate

Comparative Side Effect Analysis

Side Effect	Melanotan I	Melanotan II	Clinical Significance
Nausea	Lower	Higher	MT-II more emetogenic
Flushing	Lower	Higher	MT-II stronger vasodilation
Sexual effects	Minimal	Significant	MT-II activates MC3R/MC4R
Mood changes	Minimal	Possible	MT-II central effects
Appetite suppression	Mild	Strong	MT-II more potent anorexigenic

Dosing Protocols

Melanotan I

Loading Phase

Dose: 0.5–1.0 mg SC per dose
Frequency: Daily for 2 weeks
Total loading dose: 7–14 mg

Maintenance

Dose: 0.5–1.0 mg SC per dose
Frequency: 1–2× per week
Duration: Ongoing (seasonal)

Timing

Evening administration (reduces nausea)
Combined with UV exposure within 24–48 hours

Melanotan II

Loading Phase

Dose: 0.25–0.50 mg SC per dose
Frequency: Daily for 5–7 days
Total loading dose: 1.25–3.5 mg

Maintenance

Dose: 0.25–0.50 mg SC per dose
Frequency: 2–3× per week
Duration: 4–8 weeks for seasonal tan

Timing

Evening administration
UV exposure within 1–2 hours of injection for optimal results

Safety Considerations

Melanin Type and Cancer Risk

Both peptides preferentially stimulate eumelanin (protective) over pheomelanin (potentially harmful)
Eumelanin absorbs UV radiation and quenches free radicals
Pheomelanin generates reactive oxygen species under UV
Net effect: improved photoprotection, but not a substitute for sunscreen

Mole Monitoring

Both peptides may darken existing moles
Regular dermatological monitoring recommended
Any atypical changes warrant immediate evaluation
Not recommended in patients with history of melanoma

Regulatory Status

Melanotan I (afamelanotide): FDA-approved as Scenesse for erythropoietic protoporphyria (EPP)
Melanotan II: Not approved for any indication; research chemical status
Both are banned by WADA for competitive athletes

Conclusion

Melanotan I and Melanotan II are effective melanocortin-based tanning agents with distinct profiles. Melanotan I offers superior receptor selectivity, lower side effects, and more natural-appearing tan, making it the preferred choice for tanning applications. Melanotan II provides faster onset but with substantially higher side effect burden, particularly nausea and sexual effects. For tanning purposes, Melanotan I represents the safer and more tolerable option, while Melanotan II’s non-selective mechanism limits its utility to contexts where its additional pharmacological effects (appetite suppression, sexual function) are desired.